News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
751,088 Results
Type
Article (68752)
Company Profile (180)
Press Release (682156)
Section
Business (211426)
Career Advice (3338)
Deals (37470)
Drug Delivery (111)
Drug Development (86722)
Employer Resources (177)
FDA (17419)
Job Trends (16120)
News (365165)
Policy (36968)
Tag
Academia (2898)
Alliances (52671)
Alzheimer's disease (1315)
Approvals (17317)
Artificial intelligence (135)
Bankruptcy (362)
Best Places to Work (12071)
Biotechnology (116)
Breast cancer (116)
Cancer (982)
Cardiovascular disease (91)
Career advice (2830)
Cell therapy (229)
Clinical research (68215)
Collaboration (352)
Compensation (173)
COVID-19 (2772)
C-suite (84)
Data (886)
Diabetes (149)
Diagnostics (6483)
Drug pricing (100)
Earnings (80771)
Employer resources (156)
Events (114889)
Executive appointments (261)
FDA (17883)
Funding (302)
Gene therapy (170)
GLP-1 (667)
Government (4928)
Healthcare (20170)
Infectious disease (2856)
Inflammatory bowel disease (115)
Interviews (636)
IPO (17008)
Job creations (4359)
Job search strategy (2357)
Layoffs (479)
Legal (9109)
Lung cancer (172)
Manufacturing (172)
Medical device (13952)
Medtech (13957)
Mergers & acquisitions (20480)
Metabolic disorders (427)
Neuroscience (1584)
NextGen Class of 2024 (7188)
Non-profit (4957)
Northern California (1226)
Obesity (252)
Opinion (237)
Patents (102)
People (61683)
Phase I (20946)
Phase II (29731)
Phase III (22517)
Pipeline (217)
Postmarket research (3208)
Preclinical (9232)
Radiopharmaceuticals (254)
Rare diseases (202)
Real estate (6721)
Regulatory (24265)
Research institute (2573)
Resumes & cover letters (518)
Southern California (1094)
Startups (3771)
United States (11969)
Vaccines (631)
Weight loss (210)
Date
Today (240)
Last 7 days (877)
Last 30 days (3077)
Last 365 days (37243)
2024 (31735)
2023 (41666)
2022 (52929)
2021 (57696)
2020 (56558)
2019 (50049)
2018 (38062)
2017 (35470)
2016 (35799)
2015 (41373)
2014 (35528)
2013 (31394)
2012 (33196)
2011 (33228)
2010 (32288)
Location
Africa (1062)
Arizona (185)
Asia (44165)
Australia (7652)
California (2729)
Canada (1174)
China (216)
Colorado (121)
Connecticut (131)
Europe (101944)
Florida (403)
Georgia (110)
Illinois (351)
Indiana (186)
Kansas (98)
Maryland (545)
Massachusetts (2245)
Michigan (155)
Minnesota (261)
New Jersey (850)
New York (852)
North Carolina (750)
Northern California (1226)
Ohio (130)
Pennsylvania (740)
South America (1469)
Southern California (1094)
Texas (383)
Washington State (318)
751,088 Results for "crohn s and colitis foundation of america ccfa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Inflammatory bowel disease
Lilly and J&J Face Off in Crohn’s Disease With Phase III Readouts at ACG 2024
Eli Lilly and Johnson & Johnson are seeking label expansions for Omvoh and Tremfya, respectively, in Crohn’s disease following approvals for ulcerative colitis. GlobalData projects total sales for Tremfya to reach $7.8 billion globally by 2029.
October 29, 2024
·
2 min read
·
Tristan Manalac
Business
Azenta Announces Collaboration with the Crohn’s & Colitis Foundation to Support its Crohn’s Disease and Ulcerative Colitis Clinical Research
Azenta, Inc. (Nasdaq: AZTA) today announced it has been selected by the Crohn’s & Colitis Foundation (the “Foundation”) as its sample management services provider for two of its large-scale prospective research cohorts, CAPTURE IBD and IBD SIRQC, which investigate pediatric and surgical care for Crohn’s disease and ulcerative colitis.
June 4, 2024
·
4 min read
BioMidwest
Geneoscopy to Present Research on Inflammatory Bowel Disease at Crohn’s & Colitis Foundation’s IBD Innovate 2024 Conference
Geneoscopy, Inc. will present research at the Crohn’s & Colitis Foundation’s IBD Innovate 2024 Conference in Cambridge, Mass., April 9-10.
April 3, 2024
·
2 min read
Biotech Beach
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™
Palisade Bio, Inc. today announced that it presented at IBD Innovate: Product Development for Crohn’s & Colitis™ held April 9-10, 2024 in Cambridge, MA.
April 10, 2024
·
4 min read
Biotech Beach
Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn’s and Colitis Foundation for Development of PALI-2108
Palisade Bio, Inc. announced the receipt of the second milestone payment to Giiant from the US Crohn’s and Colitis Foundation, through its Inflammatory Bowel Disease Ventures program.
December 28, 2023
·
4 min read
Inotrem Receives Milestone Funding From the Crohn’s & Colitis Foundation IBD Ventures Program to Advance Its Inflammatory Bowel Disease Pipeline
Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced it received the second milestone-based funding from the American Crohn’s & Colitis Foundation’s IBD Ventures program.
November 6, 2023
·
3 min read
Biotech Beach
Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress
Palisade Bio, Inc. today announced the presentation of positive preclinical data of its lead asset, PALI-2108 at the Crohn’s & Colitis Congress, which was held on January 25-27, 2024 in Las Vegas, NV.
January 29, 2024
·
6 min read
Biotech Beach
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
Organovo Holdings, Inc. (NASDAQ: ONVO) based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as strong preclinical data, today announced that its data on the activity of FXR314 in its proprietary 3D human tissue models of Crohn’s disease and ulcerative colitis will be presented at the Crohn’s and Colitis Congress to be held January 25-27, 2024 in Las Vegas, Nevada.
January 9, 2024
·
3 min read
Inflammatory bowel disease
Ventyx Ends Development of TYK2 Inhibitor After Phase II Flop in Crohn’s Disease
Back-to-back failures in psoriasis and Crohn’s disease have forced Ventyx Biosciences to abandon the development of its investigational oral TYK2 inhibitor VTX958.
July 30, 2024
·
2 min read
·
Tristan Manalac
Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn’s and Colitis Organization (ECCO)
Abivax SA announced that four scientific abstracts on its lead drug candidate, obefazimod for the treatment of moderately to severely active ulcerative colitis, will be presented during the 19th Congress of the European Crohn’s and Colitis Organisation on February 21-24, 2024, in Stockholm, Sweden.
February 13, 2024
·
7 min read
1 of 75,109
Next